Literature DB >> 26613635

Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.

Rodrigo Mendoza-Sanchez1, David Cotnoir-White2, Justyna Kulpa2, Isabel Jutras2, Joshua Pottel1, Nicolas Moitessier1, Sylvie Mader3, James L Gleason4.   

Abstract

The combination of antiestrogens and histone deacetylase inhibitors (HDACi) has been found to be antiproliferative in breast cancer models. We designed and synthesized hybrid structures which combined structural features of the pure antiestrogen ICI-164,384 and HDACi's SAHA and entinostat in a single bifunctional molecule. The hybrids retained antiestrogenic and HDACi activity and, in the case of benzamide hybrids, were selective for Class I HDAC3 over Class II HDAC6. The hybrids possessed low micromolar to high nanomolar activity against both ER+ MCF-7 and ER- MDA-MB-231 breast cancer cell models.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiestrogens; Breast cancer; Estrogen receptor; HDACi

Mesh:

Substances:

Year:  2015        PMID: 26613635     DOI: 10.1016/j.bmc.2015.11.005

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

Review 1.  Histone Deacetylase Inhibitors: A Prospect in Drug Discovery.

Authors:  Rakesh Yadav; Pooja Mishra; Divya Yadav
Journal:  Turk J Pharm Sci       Date:  2018-12-31

2.  Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells.

Authors:  Mariangela Librizzi; John Spencer; Claudio Luparello
Journal:  Int J Mol Sci       Date:  2016-07-30       Impact factor: 5.923

Review 3.  Drug conjugates-an emerging approach to treat breast cancer.

Authors:  Mahmud Hasan; Rehana K Leak; Robert E Stratford; Darius P Zlotos; Paula A Witt-Enderby
Journal:  Pharmacol Res Perspect       Date:  2018-07-05

Review 4.  Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.

Authors:  Robert Jenke; Nina Reßing; Finn K Hansen; Achim Aigner; Thomas Büch
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.